Incubated by Vision Institute, the retinal disease gene therapy developer has secured $52.8m in a round co-led by UPMC Enterprises.
UPMC Enterprises, the commercialisation and venture capital arm of University of Pittsburgh Medical Center, co-led a €44.5m ($52.8m) funding round for France-based ocular therapy developer SparingVision on Wednesday.
The round was co-led by investment firm 4Bio Capital and included Bpifrance, Foundation Fighting Blindness, Jeito Capital and Ysios Capital.
Incubated by research centre Vision Institute’s incubator, Incubateur Voir & Entendre, in 2016, SparingVision is working on gene therapies for blinding retinal disorders. Its lead drug candidate, SPVN06, is being…
